NCT00538434

Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years

An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 227 (actual)
• Sponsor: Ception Therapeutics · Industry
• Sex: All
• Age: 5 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

This trial will study three doses of reslizumab versus placebo in children with eosinophilic esophagitis (EE). The objectives of the trial will be to study the effectiveness of reslizumab in improving the clinical signs and symptoms and reducing esophageal eosinophils as well as assessing the safety profile compared to placebo.

Conditions

• Eosinophilic Esophagitis

Interventions

Type	Name	Description
BIOLOGICAL	Reslizumab
OTHER	Saline

Timeline

• Start date: 2008-03-01
• Primary completion: 2009-10-01
• Completion: 2009-10-01
• First posted: 2007-10-02
• Last updated: 2016-09-02
• Results posted: 2016-09-02

Locations

37 sites across 2 countries: United States, Canada